相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches
Fabio Salvatore Macaluso et al.
INFLAMMATORY BOWEL DISEASES (2021)
Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease
Rosa Lovero et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients
Antonio Tursi et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar
Cristiano Pagnini et al.
INFLAMMATORY BOWEL DISEASES (2020)
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy
Alessandro Armuzzi et al.
INFLAMMATORY BOWEL DISEASES (2019)
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
Brian G. Feagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study
Antoine Meyer et al.
ANNALS OF INTERNAL MEDICINE (2019)
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease
Gionata Fiorino et al.
INFLAMMATORY BOWEL DISEASES (2018)
Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study
Cristina Scavone et al.
BIODRUGS (2018)
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2017)
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar
Gionata Fiorino et al.
INFLAMMATORY BOWEL DISEASES (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials
A. Cholapranee et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Krisztina B. Gecse et al.
JOURNAL OF CROHNS & COLITIS (2016)
Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
J. Sieczkowska et al.
JOURNAL OF CROHNS & COLITIS (2016)
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis
Radan Keil et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
Sang Hyoung Park et al.
Expert Review of Gastroenterology & Hepatology (2015)
Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study
Jørgen Jahnsen et al.
Expert Review of Gastroenterology & Hepatology (2015)
Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series
Yun-Seong Kang et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
The economic burden of TNF alpha inhibitors and other biologic treatments in Norway
Jan Norum et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Predicting the Crohn's disease activity index from the Harvey-Bradshaw index
WR Best
INFLAMMATORY BOWEL DISEASES (2006)
American Gastroenterological Association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2006)
Review article: infliximab therapy for inflammatory bowel disease - seven years on
P Rutgeerts et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
分享论文
